EMA Has Launched Its First Trial Of The Experimental Vaccine Against COVID-19
The European Medicines Agency (EMA) has launched its first trial of the experimental vaccine against COVID-19, being developed by Oxford University and AstraZeneca.The Agency hopes that the process will speed up its eventual approval.The agency began analyzing preliminary information from scientists about the so-called Oxford vaccine, which suggests that it "triggers the production of antibodies and T-cells."According to the agency, it is waiting for data from the last stage of tests, which are attended by thousands of people, and agency hopes that they will share them in the coming months.They used a similar process to approve remdesivir, the only medicine approved for the treatment of COVID-19.She approved the drug after about a month, and the normal process takes almost seven months.During the final testing of the Oxford vaccine, one of the participants in the United Kingdom recently developed an adverse neurological reaction, for which the British suspended testing but had in the meantime resumed testing.In the United States, similar testing is suspended until the US Food and Drug Administration reviews the report of a side effect of the vaccine.